LYEL - Lyell Immunopharma, Inc.

QQQ $ 612.14 $ 1.56 (0.26 %)

DIA $ 470.45 $ 1.64 (0.35 %)

SPY $ 672.31 $ 2.95 (0.44 %)

TLT $ 89.45 $ -0.19 (-0.21 %)

GLD $ 367.77 $ 0.35 (0.1 %)

Previous Close

$ 17.51

Open

$ 17.43

Bid

$ 13.50 x 100

Ask

$ 18.50 x 1

Day's Range

$ 16.57 - $ 17.73

52 Week Range

$ 7.65 - $ 25.40

Volume

21,459

Average Volume

Market Cap

336.39M

Beta (5Y Monthly)

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-11-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-06-2024	03-31-2024	10-Q
7	02-28-2024	12-31-2023	10-K
8	11-07-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-04-2023	03-31-2023	10-Q
11	02-28-2023	12-31-2022	10-K
12	11-08-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-10-2022	03-31-2022	10-Q
15	03-29-2022	12-31-2021	10-K
16	11-12-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Lyell Immunopharma To Present Two Abstract...
11/03/2025 14:02:34

Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therap...

Lyell Immunopharma Appoints CEO Lynn Seely...
11/03/2025 13:44:25

On October 31, 2025, the Board of Directors of Lyell Immunopharma, Inc. (the "Company") appointed Lynn Seely, M.D., the...

this-united-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday

This United Therapeutics Analyst Begins Co...
09/26/2025 12:03:22

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

LUCID CAPITAL MARKETS Initiates Coverage O...
09/26/2025 11:22:14

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Lyell Immunopharma (NASDAQ: LYEL) with a Buy rating and ...

Lyell Immunopharma CFO Charles Newton To R...
09/16/2025 20:24:30

On September 15, 2025, Charles Newton notified Lyell Immunopharma, Inc. (the "Company") of his decision to resign from ...

Lyell Immunopharma Initiates Pinacle - H2H...
09/03/2025 12:10:06

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator's choice of approved CD19 CAR T-cell ...

Lyell Immunopharma Initiates Phase 3 Head-...
09/03/2025 12:09:57

Lyell Immunopharma Q2 EPS $(2.89) Beats $(...
08/12/2025 20:34:57

Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(2.89) per share which beat the analyst consensus estimate of $(...

12 Health Care Stocks Moving In Thursday's...
07/31/2025 21:07:05

Lyell Immunopharma Announces Equity Privat...
07/25/2025 12:06:55

applied-materials-to-rally-around-28-here-are-10-top-analyst-forecasts-for-tuesday

Applied Materials To Rally Around 28%? Her...
06/24/2025 13:06:06

HC Wainwright & Co. Maintains Neutral on L...
06/24/2025 11:01:53

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Neutral and raises the pri...

Lyell Immunopharma Announced New Clinical ...
06/17/2025 10:32:50

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients t...

12 Health Care Stocks Moving In Thursday's...
06/05/2025 17:06:23

Trading Halt: Halted at 7:50:00 p.m. ET - ...
05/30/2025 23:50:04

Lyell Immunopharma Q1 EPS $(0.18) Beats $(...
05/13/2025 20:59:50

Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(...

Lyell Immunopharma Presents Clinical Data ...
05/01/2025 13:02:43

HC Wainwright & Co. Reiterates Neutral on ...
04/16/2025 11:28:19

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Neutral and maintains $1 ...

$lyell-immunopharma-receives-regenerative-medicine-advanced-therapy-designation-for-lyl314-in-treatment-of-relapsed-andor-refractory-large-b-cell-lymphoma$

Lyell Immunopharma Receives Regenerative M...
04/15/2025 13:01:13

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
03/19/2025 17:06:05